A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

Aclaris Therapeutics

Status and phase: Completed; Phase 2

Conditions: Dermatosis Papulosa Nigra

Treatments: Drug: A-101 Topical Solution 40%

Study type: Interventional

Funder types: Industry

Identifiers

NCT03224598

A-101-DPN-201

Details and patient eligibility

About

Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.

Full description

The main objective of this study is to evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.

The secondary objectives of this study include:

• Durability of response
• Safety

An exploratory objective of this study will evaluate the subject's assessment of the treatment of A-101 to DPN lesions using a Subject Self-Assessment Scale.

Enrollment: 39 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Provisions of written informed consent for participation in this study.
2. Male or female ≥ 18 years old.
3. Subject has a clinical diagnosis of dermatosis papulose nigra.
4. Fitzpatrick Skin Type of 5 or 6
5. Subject has 4 target DPN lesions located in an area that has not been previously treated.
6. Subject chemistry and complete blood count results are within normal limits for the central laboratory.
7. Woman of childbearing potential must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study
8. Subject is non-pregnant and non-lactating.
9. Subject is in good general health and free of any known disease state or physical condition.
10. Subject is willing and able to follow all study instructions and to attend all study visits.

Exclusion criteria

1. Subject has clinically atypical and /or rapidly growing DPN lesion.

2. Subject has current systemic malignancy.

3. Subject has a history of keloids

4. Subject has a history of post inflammatory hyperpigmentation lasting longer than 1 year.

5. Subject has used any of the following systemic therapies within the specified period prior to Visit 1:

   • Retinoids; 180 days
   • Corticosteroids; 28 days
   • Antimetabolites (e.g., methotrexate); 28 days

6. Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to any Target Lesion, that in the investigator's opinion interferes with the study medication treatment or the study assessments:

   • LASER, light or other energy based therapy (e.g., intense pulsed light [IPL], photo-dynamic therapy [PDT]; 180 days
   • Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-fluoruracil (5FU), or ingenol mebutate; 60 days
   • Retinoids; 28 days
   • Microdermabrasion or superficial chemical peels; 14 days
   • Corticosteroids or antibiotics; 14 days.

7. Subject currently has or has had any of the following within the specified period prior to Visit 1 on or in a proximity to any Target Lesion that, in the investigator's opinion, interferes with the study medication treatment or the study assessments:

   • Cutaneous malignancy; 180 days
   • Sunburn; currently
   • Pre-malignancy (e.g. actinic keratosis); currently
   • Body art (e.g. tattoos, piercing, etc.); currently
   • Excessive tan. The use of self-tanning lotions/sprays are prohibited.

8. Subject has a history of sensitivity to any of the ingredients in the study medications.

9. Subject has any current skin disease (e.g. psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g. sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations.

10. Participation in another therapeutic investigational drug trial in which administration of an investigational study medication occurred with 30 days prior to Visit 1.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

39 participants in 3 patient groups

No medical abrading

Experimental group

Description:

A-101 40% without medically abrading the identified DPN prior to treatment

Treatment:

Drug: A-101 Topical Solution 40%

Medically abrading

Experimental group

Description:

A-101 40% with the identified DPN lesions medically abraded prior to treatment

Treatment:

Drug: A-101 Topical Solution 40%

Initial cohort - no medical abrading

Experimental group

Description:

A-101 40% without medically abrading the identified DPN prior to treatment

Treatment:

Drug: A-101 Topical Solution 40%